Vip Enhances Phagocytosis Of Fibrillar Beta-Amyloid By Microglia And Attenuates Amyloid Deposition In The Brain Of App/Ps1 Mice

Min Song,Jia-xiang Xiong,Yan-yan Wang,Jun Tang,Bo Zhang,Yun Bai
DOI: https://doi.org/10.1371/journal.pone.0029790
IF: 3.7
2012-01-01
PLoS ONE
Abstract:Vasoactive intestinal peptide (VIP) is a multifunctional neuropeptide with demonstrated immunosuppressive and neuroprotective activities. It has been shown to inhibit Amyloid beta (A beta)-induced neurodegeneration by indirectly suppressing the production and release of a variety of inflammatory and neurotoxic factors by activated microglia. We demonstrated that VIP markedly increased microglial phagocytosis of fibrillar A beta 42 and that this enhanced phagocytotic activity depended on activation of the Protein kinase C (PKC) signaling pathway. In addition, VIP suppressed the release of tumor necrosis factor alpha (TNF-alpha) and nitric oxide(NO) from microglia activated by combined treatment with fibrillar A beta 42 and low dose interferon-gamma (IFN-gamma). We utilized an adenovirus-mediated gene delivery method to overexpress VIP constitutively in the hippocampus of APPswPS1 transgenic mice. The A beta load was significantly reduced in the hippocampus of this animal model of Alzheimer's disease, possibly due to the accumulation and activation of cd11b-immunoactive microglial cells. The modulation of microglial activation, phagocytosis, and secretion by VIP is a promising therapeutic option for the treatment of Alzheimer's disease(AD).
What problem does this paper attempt to address?